Treatment of mice with recombinant preparations of the cytokine mimetic led to an increased CD8+: Treg ratio and improved therapeutic effects compared to murine IL2 in mouse cancer models, suggesting that the new cytokine may be more suitable for pharmaceutical applications. This evidence concerns the gene CD8A and cancer.